Abstract
A new monoclonal antibody designated FO23C5 against a protein component of carcinoembryonic antigen (CEA) has been developed. A xenograft system of human colon cancer was used to compare the intact monoclonal IgG with its fragments ((Fab’)2 and Fab) and with an established anti-CEA antibody (MAb35) and the antibody AUA1 raised against the colon carcinoma cell line. We demonstrate that FO23C5 compares well with the existing anti-CEA antibody and with AUA1, and that F(ab’)2 fragments perform best in achieving optimal tumour to normal tissue ratios compared with intact IgG and Fab fragment.
Get full access to this article
View all access options for this article.
